Cited by 571Bacterial Infections and VaccinesMicrobial infections and disease researchNeonatal and Maternal Infections

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction

Trotter, Caroline L, Andrews, Nick J, Kaczmarski, Edward B, Miller, Elizabeth, Ramsay, Mary E·2004·The Lancet

Open this paper in CoChat — free account

Abstract

The meningococcal serogroup C conjugate (MCC) vaccine programme in England has successfully controlled the incidence of serogroup C disease, as a result of high short-term vaccine effectiveness and substantial herd immunity. However, the long-term effectiveness of the vaccine remains unknown. We assessed surveillance data from the 4 years since introduction of the programme. Vaccine effectiveness remained high in children vaccinated in the catch-up campaign (aged 5 months to 18 years). However, for children vaccinated in the routine infant immunisation programme, the effectiveness of the MCC vaccine fell to low levels after only 1 year. The number of individuals in these cohorts remains low, but alternative routine immunisation schedules should be considered to ensure high levels of protection are sustained.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(04)16725-1

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story
Miller, E. J., SALISBURY, D. M., & Ramsay, M. E. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00299-7 · Cited by 483
Self-citation
Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis
Ramsay, M. E., Andrews, N. J., Trotter, C. L., Kaczmarski, E. B., & Miller, E. (2003) · BMJ · doi:10.1136/bmj.326.7385.365 · Cited by 409
Self-citation
Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England
Ramsay, M. E., Andrews, N. J., Kaczmarski, E. B., & Miller, E. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03594-7 · Cited by 337
Self-citation
Estimating Haemophilus influenzae Type b Vaccine Effectiveness in England and Wales by Use of the Screening Method
Ramsay, M. E., McVernon, J., Andrews, N. J., Heath, P. T., & Slack, M. P. (2003) · The Journal of Infectious Diseases · doi:10.1086/376997 · Cited by 172
Self-citation
Antibody Persistence and Immunological Memory at Age 4 Years after Meningococcal Group C Conjugate Vaccination in Children in the United Kingdom
Borrow, R., Goldblatt, D., Andrews, N. J., Southern, J., Ashton, L., Deane, S., Morris, R., Cartwright, K. A. V., & Miller, E. (2002) · The Journal of Infectious Diseases · doi:10.1086/344324 · Cited by 114
Self-citation

Show all 5 references

Research works printed but not linked: 1

Quarterly Communicable Disease Reports on the COVER programme for childhood immunisation

Sorted by citations

Items 301–400 of 571

Meningococcal Conjugate Vaccine in Adolescents and Children
Pichichero, M. E. (2005) · Clinical Pediatrics · doi:10.1177/000992280504400603 · Cited by 17
Mucosal immunity and optimizing protection with meningococcal serogroup B vaccines
Heyderman, R. S., Davenport, V., & Williams, N. (2006) · Trends in Microbiology · doi:10.1016/j.tim.2006.01.007 · Cited by 18
Antibiotic Resistance in Neisseria
Bash, M. C., & Matthias, K. (2017) · Springer eBooks · doi:10.1007/978-3-319-47266-9_6 · Cited by 17
Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine
Kitchin, N. R. E., Southern, J., Morris, R., Borrow, R., Fiquet, A., Boisnard, F., Thomas, S., & Miller, E. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.06.049 · Cited by 17
Self-citation
Interchangeability of meningococcal group C conjugate vaccines with different carrier proteins in the United Kingdom infant immunisation schedule
Ladhani, S. N., Andrews, N. J., Waight, P., Hallis, B., Matheson, M., England, A., Findlow, H., Bai, X., Borrow, R., Burbidge, P., et al. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.12.018 · Cited by 17
Self-citation
Safety and Immunogenicity of the Quadrivalent Meningococcal Serogroups A, C, W and Y Tetanus Toxoid Conjugate Vaccine Coadministered With Routine Childhood Vaccines in European Infants
Arribas, J. M. M., Martínez, A. C., Horn, M. R., Porcuna, X. M. P., Reigada, M. D. C. O., Bermúdez, J. M., Centeno-Malfaz, F., Miranda, M., Hernández, M. J. M., Cabezas, M. Á. G., et al. (2016) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000001484 · Cited by 17
Evaluation of the impact of serogroup C meningococcal disease vaccination program in Brazil and its regions: a population-based study, 2001-2013
de Moraes, C., de Moraes, J. C., da Silva, G. D. M., & Duarte, E. C. (2017) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/0074-02760160173 · Cited by 17
A conjugate vaccine composed of a heat shock protein 60 T-cell epitope peptide (p458) and Neisseria meningitidis type B capsular polysaccharide
Amir-Kroll, H., Riverón, L., Sarmiento, M. E., Sierra, G., Acosta, A., & Cohen, I. R. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.06.019 · Cited by 17
A Multivalent Conjugate Vaccine for Prevention of Meningococcal Disease in Infants
Harrison, L. H. (2008) · JAMA · doi:10.1001/jama.2007.57-c · Cited by 17
What is the best way to use conjugate vaccines?
Seale, A. C., & Finn, A. H. R. (2011) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3283468996 · Cited by 16
MCV vaccination in the presence of vaccine-associated Guillain–Barré Syndrome risk: A decision analysis approach
Cho, B., Clark, T. A., Messonnier, N. E., Ortega‐Sanchez, I. R., Weintraub, E., & Messonnier, M. L. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.10.050 · Cited by 16
Effectiveness of vaccinating household contacts in addition to chemoprophylaxis after a case of meningococcal disease: a systematic review
Hoek, M. R., Christensen, H., Hellenbrand, W., Stefanoff, P., Howitz, M. F., & Stuart, J. M. (2008) · Epidemiology and Infection · doi:10.1017/s0950268808000770 · Cited by 16
Functional T-Cell Deficiency in Adolescents Who Experience Serogroup C Meningococcal Disease despite Receiving the Meningococcal Serogroup C Conjugate Vaccine
Foster, R., Carlring, J., Lees, A., Borrow, R., Ramsay, M. E., Kacsmarski, E., Miller, E., McKendrick, M. W., Heath, A. W., & Read, R. C. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00481-09 · Cited by 16
Self-citation
Polysaccharide-Specific Memory B Cells Generated by Conjugate Vaccines in Humans Conform to the CD27+IgG+ Isotype–Switched Memory B Cell Phenotype and Require Contact-Dependent Signals from Bystander T Cells Activated by Bacterial Proteins To Differentiate into Plasma Cells
Clarke, E. T., Williams, N., Findlow, J., Borrow, R., Heyderman, R. S., & Finn, A. H. R. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203254 · Cited by 18
FightingNeisseria meningitidis: past and current vaccination strategies
Piccini, G., Torelli, A., Gianchecchi, E., Piccirella, S., & Montomoli, E. (2016) · Expert Review of Vaccines · doi:10.1080/14760584.2016.1187068 · Cited by 16
Fast and accurate dynamic estimation of field effectiveness of meningococcal vaccines
Argante, L., Tizzoni, M., & Medini, D. (2016) · BMC Medicine · doi:10.1186/s12916-016-0642-2 · Cited by 14
Post-Licensure Safety of the Meningococcal Group C Conjugate Vaccine
Andrews, N. J., Stowe, J., Miller, E., & Taylor, B. (2007) · Human Vaccines · doi:10.4161/hv.3.2.3878 · Cited by 16
Self-citation
Identification of the serotypes of bacterial meningitis agents; implication for vaccine usage.
Yazdi, M. M. A., Ghamarian, A., Mousaviehzadeh, M., & Davoudi, N. (2014) · Europe PMC (PubMed Central) · Cited by 16
Cost-utility analysis of a nationwide vaccination programme against serogroup B meningococcal disease in Israel
Ginsberg, G. M., Block, C., & Stein‐Zamir, C. (2016) · International Journal of Public Health · doi:10.1007/s00038-016-0821-0 · Cited by 16
Immunization strategies for the control of serogroup C meningococcal disease in developed countries
Wals, P. D. (2006) · Expert Review of Vaccines · doi:10.1586/14760584.5.2.269 · Cited by 16
Calendario vacunal de la Asociación Española de Pediatría: recomendaciones 2005
de Pediatría, C. A. D. V. D. L. A. E. (2005) · Anales de Pediatría · doi:10.1157/13071314 · Cited by 16
The impact of pre-existing antibody on subsequent immune responses to meningococcal A-containing vaccines
Idoko, O. T., Okolo, S. N., Plikaytis, B. D., Akinsola, A., Viviani, S., Borrow, R., Carlone, G. M., Findlow, H., Elie, C. M., Kulkarni, P. S., et al. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.04.052 · Cited by 15
Epidémiologie des méningites bactériennes de l'enfant en France
Sarlangue, J., Lévy, C., Cohen, R., Bingen, É., & Aujard, Y. (2006) · Archives de Pédiatrie · doi:10.1016/j.arcped.2006.03.016 · Cited by 15
Cobertura da vacina meningocócica C nos estados e regiões do Brasil em 2012
Neves, R. G., Wendt, A. T., Costa, C. D. S., Flores, T. R., Soares, A. G., & Wehrmeister, F. C. (2016) · Revista Brasileira de Medicina de Família e Comunidade · doi:10.5712/rbmfc11(38)1122 · Cited by 14
Immunogenicity of conjugate Meningococcus C vaccine in pediatric solid organ transplant recipients
Zlamy, M., Elias, J., Vogel, U. F., Frosch, M., Jeller, V., Cortina, G., Jungraithmayr, T., & Prelog, M. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.06.033 · Cited by 15
A Consensus Statement
Rüttimann, R. W., de Gentile, A. S., Parra, M. M., Sáez‐Llorens, X., Sáfadi, M. A. P., & Santolaya, M. E. (2014) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000000228 · Cited by 15
Immunogenicity of 10-Valent Pneumococcal Nontypeable Haemophilus Influenzae Protein D Conjugate Vaccine When Administered as Catch-up Vaccination to Children 7 Months to 5 Years of Age
Vesikari, T., Karvonen, A., Korhonen, T., Karppa, T., Sadeharju, K., Fanic, A., Dieussaert, I., & Schuerman, L. (2011) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31821d1790 · Cited by 15
Recognising serious illness in feverish young children in primary care
Harnden, A. (2007) · BMJ · doi:10.1136/bmj.39295.383843.ad · Cited by 15
The Influence of IS1301 in the Capsule Biosynthesis Locus on Meningococcal Carriage and Disease
Kugelberg, E., Gollan, B., Farrance, C., Bratcher, H. B., Lucidarme, J., Ibarz-Pavón, A. B., Maiden, M. C. J., Borrow, R., & Tang, C. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009413 · Cited by 15
Effect of Increased CRM197Carrier Protein Dose on Meningococcal C Bactericidal Antibody Response
Lee, L. H., & Blake, M. S. (2012) · Clinical and Vaccine Immunology · doi:10.1128/cvi.05438-11 · Cited by 15
Cost-effectiveness of alternate strategies for childhood immunization against meningococcal disease with monovalent and quadrivalent conjugate vaccines in Canada
Delea, T. E., Weycker, D. A., Atwood, M., Neame, D., Alvarez, F. P., Forget, E. L., Langley, J. M., & Chit, A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175721 · Cited by 15
Early Appearance of Bactericidal Antibodies after Polysaccharide Challenge of Toddlers Primed with a Group C Meningococcal Conjugate Vaccine: What Is Its Role in the Maintenance of Protection?
Tsai, T. F., Borrow, R., Gnehm, H. E., Vaudaux, B. P., Heininger, U., Desgrandchamps, D., Aebi, C., Balmer, P., Pedersen, R. D., Fritzell, B., et al. (2006) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00059-06 · Cited by 15
Meningococcal vaccines
Granoff, D. M., Pelton, S. I., & Harrison, L. H. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0090-5.00029-x · Cited by 16
Vaccine Prevention of Meningococcal Disease: Making Slow Progress
Harrison, L. H. (2006) · Clinical Infectious Diseases · doi:10.1086/508780 · Cited by 15
Antibody Persistence in Australian Adolescents Following Meningococcal C Conjugate Vaccination
Perrett, K. P., Richmond, P., Borrow, R., Nolan, T. M., & McVernon, J. (2015) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000000541 · Cited by 14
Comparison of a limiting dilution assay and ELISpot for detection of memory B-cells before and after immunisation with a protein-polysaccharide conjugate vaccine in children
Rohner, G. B., Galli, G., Clutterbuck, E., & Pollard, A. J. (2010) · Journal of Immunological Methods · doi:10.1016/j.jim.2010.03.014 · Cited by 14
Kinetics of Immune Responses to Nasal Challenge With Meningococcal Polysaccharide One Year After Serogroup-C Glycoconjugate Vaccination
Wing, J. B., Smart, L. E., Borrow, R., Findlow, J., Findlow, H., Heath, A. W., & Read, R. C. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir198 · Cited by 14
Density Distribution of Pharyngeal Carriage of Meningococcus in Healthy Young Adults
Finn, A. H. R., Morales‐Aza, B. M., Sikora, P., Giles, J., Lethem, R., Marlais, M., Thors, V. S., Pollard, A. J., Faust, S. N., Heath, P. T., et al. (2016) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000001237 · Cited by 14
Overcoming the need for a cold chain with conjugated meningococcal Group C vaccine: A controlled, randomized, double-blind study in toddlers on the safety and immunogenicity of Menjugate®, stored at room temperature for 6 months
Schöndorf, I., Banzhoff, A., Nicolay, U., & Díaz‐Mitoma, F. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.10.022 · Cited by 14
A cross-sectional study assessing the pharyngeal carriage of Neisseria meningitidis in subjects aged 1–24 years in the city of Embu das Artes, São Paulo, Brazil
Weckx, L. Y., Puccini, R. F., Machado, A. M. O., Gonçalves, M. G., Tuboi, S. H., de Barros, E., Devadiga, R., Ortega‐Barría, E., & Colindres, R. E. (2017) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2017.06.005 · Cited by 14
Immunogenicity, safety and tolerability of meningococcal C CRM197 conjugate vaccine administered 3, 5 and 11 months post-natally to pre- and full-term infants
Esposito, S., Corbellini, B., Bosis, S., Pugni, L., Tremolati, E., Tagliabue, C., Toneatto, D., Mosca, F., & Principi, N. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.04.018 · Cited by 14
Expanding prevention of invasive meningococcal disease
Pelton, S. I., & Gilmet, G. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.37 · Cited by 14
Carbohydrate‐Based Antibacterial Vaccines
Pon, R. A., & Jennings, H. J. (2008) · Wiley eBooks · doi:10.1002/9780470473283.ch4 · Cited by 14
Persistence of Serum Bactericidal Antibody One Year After a Booster Dose of Either a Glycoconjugate or a Plain Polysaccharide Vaccine Against Serogroup C Neisseria meningitidis Given to Adolescents Previously Immunized With a Glycoconjugate Vaccine
de Whalley, P., Snape, M. D., Kelly, D. F., Banner, C., Lewis, S., Diggle, L., John, T. M., Yu, L., Omar, O., Borkowski, A., et al. (2011) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e318224fb14 · Cited by 13
Effectiveness of different vaccine schedules for heptavalent and 13-valent conjugate vaccines against pneumococcal disease in the Community of Madrid
Zamalloa, P. L., Ordobás, M., Garrido‐Estepa, M., de Miguel, Á. G., Sanz, J. C., Ordoñez, M. D. B., Marisquerena, E. I., & García-Comas, L. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.07.089 · Cited by 13
Reduction inNeisseria meningitidisinfection in Italy after Meningococcal C conjugate vaccine introduction: A time trend analysis of 1994–2012 series
de Waure, C., Miglietta, A., Nedovic, D., Mereu, G., & Ricciardi, W. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1078951 · Cited by 13
Sustaining immunity after immunization against encapsulated bacteria
Rohner, G. B., & Pollard, A. J. (2008) · Human Vaccines · doi:10.4161/hv.4.4.5437 · Cited by 13
Meningococcal tetravalent conjugate vaccine
Smith, M. J. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712590802538455 · Cited by 13
Experience with MCV-4, a meningococcal, diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135
KEYSERLING, H. L., Pollard, A. J., DeTora, L. M., & Gilmet, G. (2006) · Expert Review of Vaccines · doi:10.1586/14760584.5.4.445 · Cited by 13
Patterns of binding of aluminum-containing adjuvants to Haemophilus influenzae type b and meningococcal group C conjugate vaccines and components
Otto, R. B. D., Burkin, K., Amir, S. E., Crane, D. T., & Bolgiano, B. (2015) · Biologicals · doi:10.1016/j.biologicals.2015.06.008 · Cited by 13
A randomized study comparing the safety and immunogenicity of a conjugate vaccine combination containing meningococcal group C and pneumococcal capsular polysaccharide—CRM197 with a meningococcal group C conjugate vaccine in healthy infants: Challenge phase
Riddell, A., Buttery, J. P., McVernon, J., Chantler, T., Lane, L., Bowen‐Morris, J., Diggle, L., Morris, R., Lockhart, S. P., Pollard, A. J., et al. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.097 · Cited by 13
Pneumococcal Conjugate Vaccine and Pneumococcal Common Protein Vaccines
Klugman, K. P., Dagan, R., Malley, R., & Whitney, C. G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00045-6 · Cited by 13
The National Service Framework for Children
Craft, A. W. (2005) · Archives of Disease in Childhood · doi:10.1136/adc.2004.066225 · Cited by 13
Universal protein vaccines againstNeisseria meningitidisserogroup B,Streptococcus pneumoniaeand influenza
Principi, N., & Esposito, S. (2011) · Human Vaccines · doi:10.4161/hv.7.9.15986 · Cited by 12
Impact of meningococcal C conjugate vaccination programs with and without catch-up campaigns in adolescents: Lessons learned from Bahia, Brazil
Macêdo, L. E. N., Ferreira, V. M., Feitosa, C. A., Nunes, A. M. P. B., Campos, L. C., & Sáfadi, M. A. P. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1415682 · Cited by 12
Spatiotemporal Analysis of Serogroup C Meningococcal Meningitis Spread in Niger and Nigeria and Implications for Epidemic Response
Cooper, L., Ronveaux, O., Fernandez, K., Lingani, C., Kadadé, G., Ihekweazu, C. A., Préziosi, M., Durupt, A., & Trotter, C. L. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz343 · Cited by 12
Self-citation
Invasion of the choroid plexus epithelium byNeisseria meningitidisis differently mediated by Arp2/3 signaling and possibly by dynamin dependent on the presence of the capsule
Herold, R., Sünwoldt, G., Stump-Guthier, C., Weiß, C., Ishikawa, H., Schroten, H., Adam, R., & Schwerk, C. (2021) · Pathogens and Disease · doi:10.1093/femspd/ftab042 · Cited by 11
Chemoprophylaxis and vaccination in preventing subsequent cases of meningococcal disease in household contacts of a case of meningococcal disease: a systematic review
Telisinghe, L., Waite, T. D., Gobin, M., Ronveaux, O., FERNANDEZ, K., STUART, J. M., & Scholten, R. J. P. M. (2015) · Epidemiology and Infection · doi:10.1017/s0950268815000849 · Cited by 12
Epidemiology and Control of Meningococcal Disease in Canada: A Long, Complex, and Unfinished Story
Wals, P. D. (2019) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2019/8901847 · Cited by 12
Two versus three doses of a meningococcal C conjugate vaccine concomitantly administered with a hexavalent DTaP-IPV-HBV/Hib vaccine in healthy infants
Schmitt, H., Steul, K., Borkowski, A., Ceddia, F., Ypma, E., & Knuf, M. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.02.041 · Cited by 12
Meningococcal Disease in International Travel: Vaccine Strategies
Wilder‐Smith, A. (2008) · Journal of Travel Medicine · doi:10.2310/7060.2005.12054 · Cited by 12
Introduction
Dagan, R., & Frasch, C. E. (2009) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e318199f5f2 · Cited by 12
Using the tetravalent meningococcal polysaccharide-protein conjugate vaccine in the prevention of meningococcal disease
Kimmel, S. R. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s962 · Cited by 13
Conjugate vaccines
Finn, A. H. R. (2005) · Archives of Disease in Childhood · doi:10.1136/adc.2005.072173 · Cited by 12
Editorial Commentary: Fifteen Years of Protection by Meningococcal C Conjugate Vaccines: Lessons From Disease Surveillance
Maiden, M. C. J., & MacLennan, J. M. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu599 · Cited by 12
Vaccines: An Important Tool for Infectious Disease
Saman, S., Chauhan, I., & Srivastava, N. (2022) · Recent Advances in Anti-Infective Drug Discovery · doi:10.2174/2772434418666221114113036 · Cited by 11
Impact on disease incidence of a routine universal and catch-up vaccination strategy against Neisseria meningitidis C in Tuscany, Italy
Bechini, A., Levi, M., Boccalini, S., Tiscione, E., Balocchini, E., Canessa, C., Azzari, C., & Bonanni, P. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.08.019 · Cited by 11
Evaluation of the Induction of Immune Memory following Infant Immunisation with Serogroup C Neisseria meningitidis Conjugate Vaccines – Exploratory Analyses within a Randomised Controlled Trial
Khatami, A., Clutterbuck, E., Thompson, A., McKenna, J. A., Pace, D., Birks, J., Snape, M. D., & Pollard, A. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101672 · Cited by 11
Optimizing Protection Against Meningococcal Disease
Reisinger, K. S., BLACK, S. B., & Stoddard, J. J. (2010) · Clinical Pediatrics · doi:10.1177/0009922809354327 · Cited by 11
Lessons learned and applied
Hebert, C., Hall, C. M., & Odoms, L. N. J. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.19204 · Cited by 11
Influenza vaccine effectiveness: best practice and current limitations of the screening method and their implications for the clinic
Minodier, L., Blanchon, T., Souty, C., Turbelin, C., Leccia, F., Varesi, L., & Falchi, A. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2014.930666 · Cited by 11
Evaluation of meningococcal serogroup C conjugate vaccine programs in Canadian children: Interim analysis
Bettinger, J. A., Scheifele, D. W., Halperin, S. A., Kellner, J. D., Vanderkooi, O. G., Schryvers, A. B., Serres, G. D., & Alcantara, J. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.034 · Cited by 11
Bacteria, polysaccharides, vaccines and boosting: measuring and maintaining population immunity
Goldblatt, D. (2008) · Archives of Disease in Childhood · doi:10.1136/adc.2007.133124 · Cited by 11
Challenges in immunisation against bacterial infection in children
Trück, J., & Pollard, A. J. (2010) · Early Human Development · doi:10.1016/j.earlhumdev.2010.08.010 · Cited by 11
A Combined Haemophilus influenzae Type B Neisseria meningitidis Serogroup C Tetanus Toxoid Conjugate Vaccine Is Immunogenic and Well-tolerated When Coadministered With Diphtheria, Tetanus, Acellular Pertussis Hepatitis B–inactivated Poliovirus at 3, 5 and 11 Months of Age
Vesikari, T., Forstén, A., Desole, M. G., Ferrera, G., Caubet, M., Mesaros, N. E., & Boutriau, D. (2012) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31827e22e3 · Cited by 11
Impact and effectiveness of meningococcal vaccines: a review
de Oliveira, L. H., Jaúregui, B., Carvalho, A. F., & Giglio, N. (2017) · Revista Panamericana de Salud Pública · doi:10.26633/rpsp.2017.158 · Cited by 13
Enfermedad meningocócica invasora
Rubio, J. A. S., & Sáez, M. M. (2005) · Anales de Pediatría · doi:10.1157/13073241 · Cited by 11
Serogroup C Neisseria meningitidis invasive infection: analysis of the possible vaccination strategies for a mass campaign
Chiappini, E., Venturini, E., Bonsignori, F., Galli, L., & de Martino, M. (2010) · Acta Paediatrica · doi:10.1111/j.1651-2227.2010.01908.x · Cited by 10
Meningococcal C conjugate age-dependant long-term loss of effectiveness
Garrido‐Estepa, M., Nunez, O. G., León-Gómez, I., Cano, R., & Herruzo, R. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.03.044 · Cited by 10
Pneumococcal polysaccharide–protein (CRM197) conjugate vaccines, 7- or 9-valent, in the 2 + 1 schedule
Fritzell, B., & Fletcher, M. A. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.11 · Cited by 10
Impact of meningococcal C conjugate vaccination campaign in Emilia-Romagna, Italy
Pascucci, M. G., Gregori, V. D., Frasca, G., Rucci, P., Finarelli, A. C., Moschella, L., Borrini, B. M., Cavrini, F., Liguori, G., Sambri, V., et al. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.27597 · Cited by 10
NeisseriaVaccines 2007
Findlow, J., Balmer, P., Yero, D., Niebla, O., Pajón, R., & Borrow, R. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.4.485 · Cited by 10
Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease
Souza, A. R., Maruyama, C., Sáfadi, M. A. P., Lopes, M. H., Azevedo, R. S., Findlow, H., Bai, X., Borrow, R., & Weckx, L. Y. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.06.072 · Cited by 10
Meningococcal Capsular Group A, C, W, and Y Conjugate Vaccines
Harrison, L. H., Granoff, D. M., & Pollard, A. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00038-9 · Cited by 11
Vacinas meningocócicas conjugadas: eficácia e novas combinações
Sáfadi, M. A. P., & Barros, A. P. (2006) · Jornal de Pediatria · doi:10.1590/s0021-75572006000400005 · Cited by 10
The impact of aggregating serogroups in dynamic models of Neisseria meningitidis transmission
Poore, K. D., & Bauch, C. T. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-1015-8 · Cited by 9
REACTOGENICITY AND IMMUNOGENICITY OF COMBINED HAEMOPHILUS INFLUENZAE TYPE B-MENINGOCOCCAL SEROGROUP C CONJUGATE VACCINE BOOSTER DOSE COADMINISTERED WITH MEASLES, MUMPS, AND RUBELLA VACCINEHIB-MENC-TT BOOSTER WITH ROUTINE MMR VACCINE
Carmona, A., Miranda, M., Barrio, F., Vicente, A. D., Marés, J., Muñoz, E., Rubio, J. D.-D., Alonso, Á., Giménez‐Sánchez, F., Merino, J., et al. (2010) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181c15977 · Cited by 9
T-Cell-Stimulating Protein A Elicits Immune Responses during Meningococcal Carriage and Human Disease
Robinson, K., Wooldridge, K. G., Wells, D. B., Hasan, A., Todd, I., Robins, A., James, R., & Ala’Aldeen, D. A. A. (2005) · Infection and Immunity · doi:10.1128/iai.73.8.4684-4693.2005 · Cited by 9
Neisseria cinerea Expresses a Functional Factor H Binding Protein Which Is Recognized by Immune Responses Elicited by Meningococcal Vaccines
Lavender, H., Poncin, K., & Tang, C. M. (2017) · Infection and Immunity · doi:10.1128/iai.00305-17 · Cited by 9
A propos d’une campagne de vaccination contre la méningite C dans les Hautes-Pyrénées : réflexions de pharmacovigilance
Bagheri, H., Gony, M., & Montastruc, J. (2005) · Therapies · doi:10.2515/therapie:2005038 · Cited by 9
Combination conjugate vaccines
Bar‐Zeev, N., & Buttery, J. P. (2006) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.3.351 · Cited by 9
Meningococcal C booster not recommended by evidence
Thomas, H. L., Andrews, N., Trotter, C. L., Ramsay, M. E., & Miller, E. (2008) · BMJ · doi:10.1136/bmj.a1139 · Cited by 9
Self-citation
Inching Toward a Serogroup B Meningococcal Vaccine for Infants
Cohn, A. C., & Messonnier, N. E. (2012) · JAMA · doi:10.1001/jama.2012.118 · Cited by 9
Calendario de vacunación de la Asociación Española de Pediatría: recomendaciones 2006
de Pediatría, C. A. D. V. D. L. A. E. (2006) · Anales de Pediatría · doi:10.1016/s1695-4033(06)70012-1 · Cited by 9
Safety and immunogenicity of an investigational quadrivalent meningococcal tetanus toxoid conjugate vaccine (MenACYW-TT) co-administered with routine pediatric vaccines in infants and toddlers: A Phase II study
Cornish, M. J., HEDRICK, J. A., Gabrielsen, A. A., Johnson, A. D., Pina, L. M., Rehm, C., Pan, J., Neveu, D., Costa, X. J. D., Jordanov, E., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.01.050 · Cited by 10
Epidemiology of meningococcal disease in the Panamanian pediatric population, 1998-2008
Guevara, J. N., Luciani, K., Melián, A. M., & Durán, M. M. (2010) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.1518 · Cited by 8
Calendário vacinal na infância e adolescência: avaliando diferentes propostas
Feijó, R. B., Cunha, J., & Krebs, L. D. S. (2006) · Jornal de Pediatria · doi:10.1590/s0021-75572006000400002 · Cited by 8
Cross-Reactive Bactericidal Antimeningococcal Antibodies Can Be Isolated From Convalescing Invasive Meningococcal Disease Patients Using Reverse Vaccinology 2.0
Bidmos, F. A., Nadel, S., Screaton, G. R., Kroll, J. S., & Langford, P. R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01621 · Cited by 8
Reassessing normal blood pressure
Nash, I. S. (2007) · BMJ · doi:10.1136/bmj.39310.540683.80 · Cited by 8
Vacuna conjugada frente al meningococo C: impacto del programa de vacunación y efectividad a largo plazo en Navarra, 2000-2014
Morales, D., Cenoz, M. G., Moreno‐Galarraga, L., Bernaola, E., Barricarte, A., & Castilla, J. (2016) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2015.11.020 · Cited by 8

Authors: Trotter, C. L., Andrews, N. J., Kaczmarski, E. B., Miller, E., & Ramsay, M. E.
Affiliations: Manchester Royal Infirmary (GB)
ORCID: Trotter, Caroline L
Andrews, Nick J
Miller, Elizabeth
Ramsay, Mary E
Venue: The Lancet
Publisher: Elsevier BV
Published: 2004-07
Volume: 364
Issue: 9431
Pages: 365-367
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(04)16725-1
OpenAlex: W2160879811
Cited by: 571
References: 5
Citations by year: 2026: 1 · 2025: 4 · 2024: 1 · 2023: 6 · 2022: 7 · 2021: 10 · 2020: 12 · 2019: 15 · 2018: 18 · 2017: 26 · 2016: 23 · 2015: 33 · 2014: 27 · 2013: 29 · 2012: 42
FWCI: 50.77
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Explore Bristol Research (publishedVersion)
Topics: Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
Life Sciences › Immunology and Microbiology › Microbiology › Microbial infections and disease research
Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal and Maternal Infections
Keywords: vaccine effectiveness, long-term vaccine effectiveness, herd immunity, catch-up vaccination, meningococcal disease incidence, vaccination schedule, England
MeSH terms: Adolescent, Adult, Age Factors, Child, Child, Preschool, England, Follow-Up Studies, Humans, Immunization Schedule, Immunization, Secondary, Infant, Meningococcal Infections, Vaccines, Conjugate, Meningococcal Vaccines, Immunity, Herd, Neisseria meningitidis, Serogroup C

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks